- Home
- SOFI vs ROIV Comparison
SOFI vs ROIV Comparison
Compare SOFI & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SOFI | ROIV |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Diversified Financial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.0B | 14.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SOFI | ROIV |
|---|---|---|
| Price | $27.29 | $22.39 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 8 |
| Target Price | ★ $24.70 | $24.31 |
| AVG Volume (30 Days) | ★ 61.2M | 7.9M |
| Earning Date | 01-26-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 357.55 | N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | ★ $3,290,639,000.00 | $20,329,000.00 |
| Revenue This Year | $37.00 | N/A |
| Revenue Next Year | $27.42 | $376.94 |
| P/E Ratio | $48.50 | ★ N/A |
| Revenue Growth | ★ 30.62 | N/A |
| 52 Week Low | $8.60 | $8.73 |
| 52 Week High | $32.73 | $23.47 |
Technical Indicators
Market Signals| Indicator | SOFI | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 49.08 | 61.61 |
| Support Level | $25.25 | $21.60 |
| Resistance Level | $26.84 | $23.47 |
| Average True Range (ATR) | 1.09 | 0.88 |
| MACD | -0.13 | 0.06 |
| Stochastic Oscillator | 39.36 | 69.09 |
Price Performance
Historical ComparisonAbout SOFI SoFi Technologies Inc.
SoFi is a financial-services company that was founded in 2011 and is based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020, the company also offers payment and account services for debit cards and digital banking.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.